Secure Asset Management LLC Cuts Stock Position in Abbott Laboratories $ABT

Secure Asset Management LLC lessened its holdings in Abbott Laboratories (NYSE:ABT) by 33.4% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 10,564 shares of the healthcare product maker’s stock after selling 5,288 shares during the period. Secure Asset Management LLC’s holdings in Abbott Laboratories were worth $1,437,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of ABT. Brighton Jones LLC increased its stake in Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock worth $5,850,000 after buying an additional 4,755 shares in the last quarter. Bank Pictet & Cie Europe AG grew its position in shares of Abbott Laboratories by 1.9% during the fourth quarter. Bank Pictet & Cie Europe AG now owns 152,719 shares of the healthcare product maker’s stock valued at $17,274,000 after purchasing an additional 2,774 shares in the last quarter. Vident Advisory LLC grew its position in shares of Abbott Laboratories by 30.2% during the fourth quarter. Vident Advisory LLC now owns 34,899 shares of the healthcare product maker’s stock valued at $3,948,000 after purchasing an additional 8,098 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Abbott Laboratories during the fourth quarter valued at about $5,997,000. Finally, Waverly Advisors LLC grew its position in shares of Abbott Laboratories by 19.1% during the fourth quarter. Waverly Advisors LLC now owns 87,165 shares of the healthcare product maker’s stock valued at $9,859,000 after purchasing an additional 13,952 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of a number of research analyst reports. Royal Bank Of Canada raised their price objective on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a research report on Tuesday, July 15th. William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. BTIG Research cut their price objective on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, July 18th. Mizuho raised their price objective on Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Finally, Wells Fargo & Company cut their price objective on Abbott Laboratories from $147.00 to $142.00 and set an “overweight” rating for the company in a research report on Friday, July 18th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $144.47.

Insider Buying and Selling

In related news, CFO Philip P. Boudreau sold 5,550 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer owned 51,003 shares of the company’s stock, valued at $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Trading Up 0.9%

ABT opened at $133.90 on Thursday. The company has a market capitalization of $233.05 billion, a P/E ratio of 16.78, a PEG ratio of 2.52 and a beta of 0.69. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The stock’s fifty day moving average is $130.36 and its two-hundred day moving average is $131.24.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, hitting analysts’ consensus estimates of $1.26. The company had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. Abbott Laboratories’s revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.